Perjeta prices near Virginia Beach, VA
Lowest: $5,396.76 Highest: $5,737.86
What is Perjeta?
USES: Pertuzumab is used to treat certain types of breast cancer. It is also used to treat early stage breast cancer in patients who will be having surgery to remove the cancer. The types of cancers pertuzumab is used to treat are tumors that produce more than the normal amount of a certain substance called HER2 protein. This medication is called a monoclonal antibody. It works by attaching to the HER2 cancer cells and blocking them from dividing and growing. It may also destroy the cancer cells or signal the body (immune system) to destroy the cancer cells.
How to take Perjeta
HOW TO USE: This medication is given by a health care professional. It is injected slowly into a vein as directed by your doctor, usually once every 3 weeks. Your first infusion will be given over 60 minutes. The dosage, the speed of your injection, and the length of time you receive pertuzumab is based on your medical condition, other treatments you are taking, and your response to pertuzumab treatment. A health care professional should watch you for at least 60 minutes after your first infusion is finished and 30 minutes after the following infusions to make sure you do not have an infusion reaction (see also Side Effects section). Use this medication regularly to get the most benefit from it. To help you remember, mark the days on the calendar when you need to receive the medication.
WARNING: Pertuzumab can cause serious (possibly fatal) harm to an unborn baby if used during pregnancy. It should only be used during pregnancy if the benefits outweigh these risks. It is important that men and women using this medication use reliable forms of birth control (such as condoms, birth control pills) while using this medication and for 7 months after treatment stops. If you become pregnant, think you may be pregnant, or cause a pregnancy, tell your doctor right away.
What if I miss a dose of Perjeta?
MISSED DOSE: For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor or pharmacist right away to establish a new dosing schedule.
STORAGE: Not applicable. This medication is given in a hospital or clinic and will not be stored at home.
Side Effects of Perjeta
SIDE EFFECTS: Diarrhea, nausea, vomiting, tiredness, and loss of appetite may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. Temporary hair loss may occur. Normal hair growth should return after treatment has ended. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: trouble breathing, numbness/tingling of arms/legs, symptoms of heart failure (such as shortness of breath, swelling ankles/feet, unusual tiredness, unusual/sudden weight gain). Pertuzumab can commonly cause a rash that is usually not serious. However, you may not be able to tell it apart from a rare rash that could be a sign of a severe reaction. Therefore, tell your doctor right away if you develop any rash. This medication may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor right away if you have any signs of infection (such as fever, chills, persistent sore throat, cough). This medication can sometimes cause a serious infusion (IV) reaction. Immediately tell your doctor if the following side effects occur while this drug is being given: chills, fever, headache, rash, vomiting, and weakness. Your doctor may decrease the speed of your injection. A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Interactions with Perjeta
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
PRECAUTIONS: Before using pertuzumab, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details. Before using this medication, tell your doctor or pharmacist your medical history, especially of: previous cancer treatments (including radiation therapy to the chest), heart disease, high blood pressure, previous severe reaction to monoclonal antibody treatment. Pertuzumab can make you more likely to get infections or may worsen any current infection. Therefore, wash your hands well to prevent the spread of infection. Avoid contact with people who have infections that may spread to others (such as chickenpox, measles, flu). Consult your doctor if you have been exposed to an infection or for more details. Do not have immunizations/vaccinations without the consent of your doctor. Avoid contact with people who have recently received live vaccines (such as flu vaccine inhaled through the nose). Wash your hands well to prevent the spread of infections. To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like razors and nail cutters, and avoid activities such as contact sports. Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products). Older adults may be more sensitive to the side effects of this drug, especially tiredness, loss of appetite and numbness/tingling of arms/legs. Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using pertuzumab. Pertuzumab may harm an unborn baby. See also Warning section. It is unknown if this medication passes into breast milk. Because of the possible risk to the infant, breast-feeding is not recommended while using this drug or for 7 months after the last dose. Consult your doctor before breast-feeding.
Conditions Commonly Treated by Perjeta
Prescription prices may vary from pharmacy to pharmacy and are subject to change. The pricing estimates given are based on the most recent information available and may change based on when you actually fill your prescription at the pharmacy. The day supply is based upon the average dispensing patterns or the specific drug and strength. The Program, as well as the prices and the list of covered drugs, can be modified at any time without notice.
Blog Posts Related to Perjeta
Streamlining the process of bringing biosimilars to market is one of the keys to facilitating innovation and reducing healthcare costs, according to US Food and Drug Administration (FDA) Commissioner Scott Gottlieb.
Speaking at the Brookings Institution on the release of the FDA’s...
Fulphila (pegfilgrastim-jmdb) is the first biosimilar to Neulasta (pegfilgrastim) to gain approval from the US Food and Drug Administration (FDA). The Mylan GmbH medicine was approved as a treatment to reduce the risk of infection as suggested by febrile neutropenia (fever caused by a lack of...
Lynparza (olaparib tablets) is the first poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with breast cancer whose tumors have a specific inherited genetic mutation. Lynparza is already approved in the United States as a treatment for a number of other cancers,...
More than four in ten (42 percent) of cancer cases in the United States are linked to risk factors associated with cancer, such as smoking, obesity, poor diet, ultraviolet radiation and physical inactivity, according to a new study conducted by the American Cancer Society. The results of the...
Overweight or obese Americans are at a higher risk of developing cancer, according to the latest Vital Signs report from the Centers for Disease Control and Prevention (CDC). At least 13 different types of cancer are associated with obesity, yet figures suggest more than half of Americans are...
Patients with HER2 breast cancer will have a new treatment option available later this year, following the US Food and Drug Administration's (FDA) approval of the first extended adjuvant treatment for the condition. Nerlynx (neratinib), a kinase inhibitor from Puma Biotechnology, was granted FDA...
A Phase III OlympiAD trial of Lynparza (olaparib) tablets for treating patients with HER2-negative gBRCA-mutated metastatic breast cancer has yielded positive results with a "statistically-significant and clinically-meaningful improvement in progression-free survival". Pharmaceutical firm...
Similar Drugs To Perjeta & Other Antineoplastic Monoclonal Antibodies